Profile data is unavailable for this security.
About the company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
- Revenue in USD (TTM)19.00m
- Net income in USD-296.87m
- Incorporated2012
- Employees480.00
- LocationUniqure NVPaasheuvelweg 25aAMSTERDAM 1105 BPNetherlandsNLD
- Phone+31 202406000
- Fax+31 202406020
- Websitehttp://www.uniqure.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Werewolf Therapeutics Inc | 16.22m | -41.58m | 224.66m | 46.00 | -- | 1.90 | -- | 13.85 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -58.67m | 228.80m | 57.00 | -- | 0.8488 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Aldeyra Therapeutics Inc | 0.00 | -30.01m | 229.34m | 10.00 | -- | 2.02 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
Nektar Therapeutics | 90.17m | -175.84m | 233.20m | 137.00 | -- | 1.84 | -- | 2.59 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -24.95 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
Akebia Therapeutics Inc | 187.23m | -43.03m | 234.75m | 167.00 | -- | -- | -- | 1.25 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.34 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 83.44 | 69.13 | -22.98 | -82.25 | 1.31 | -4.82 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
Acrivon Therapeutics Inc | 0.00 | -64.12m | 238.37m | 58.00 | -- | 1.62 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Codexis Inc | 74.23m | -65.13m | 238.48m | 174.00 | -- | 3.01 | -- | 3.21 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Metagenomi Inc | 44.76m | -68.26m | 239.02m | 236.00 | -- | -- | -- | 5.34 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
Uniqure NV | 19.00m | -296.87m | 240.32m | 480.00 | -- | 1.64 | -- | 12.65 | -6.20 | -6.20 | 0.3967 | 3.03 | 0.0271 | 2.70 | 0.329 | 39,589.58 | -42.38 | -12.43 | -46.71 | -13.46 | -7.45 | -- | -1,562.22 | -51.35 | 9.27 | -8.72 | 0.7757 | -- | -85.12 | 7.02 | -143.30 | -- | 11.00 | -- |
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 242.74m | 49.00 | -- | 5.46 | -- | 2,996.73 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Century Therapeutics Inc | 1.37m | -133.47m | 247.03m | 152.00 | -- | 1.08 | -- | 180.32 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
AVITA Medical Inc | 50.70m | -44.82m | 247.94m | 207.00 | -- | 7.61 | -- | 4.89 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 250.66m | 133.00 | -- | 1.36 | -- | 235.58 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Sanara Medtech Inc | 68.00m | -4.89m | 256.17m | 107.00 | -- | 5.92 | -- | 3.77 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
MacroGenics Inc | 43.36m | -23.24m | 256.17m | 339.00 | -- | 2.41 | -- | 5.91 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
Holder | Shares | % Held |
---|---|---|
Vestal Point Capital LPas of 31 Mar 2024 | 4.73m | 9.88% |
Nantahala Capital Management LLCas of 31 Mar 2024 | 3.09m | 6.46% |
683 Capital Management LLCas of 31 Mar 2024 | 1.98m | 4.13% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.49m | 3.13% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.47m | 3.08% |
Schroder Investment Management Ltd.as of 31 Mar 2024 | 1.24m | 2.60% |
SV Health Managers LLPas of 30 Sep 2023 | 1.24m | 2.60% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.06m | 2.21% |
D. E. Shaw & Co. LPas of 31 Mar 2024 | 850.10k | 1.78% |
BNP Paribas Financial Marketsas of 31 Mar 2024 | 736.72k | 1.54% |